ascopubs.org

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer Patients with solid tumors amenable to pharmacokinetic and ...
FierceBiotech

Daiichi Sankyo To License ARQ 092 from ArQule, the First New Compound Resulting from the Companies' Joint AKIP Research Collabor

WOBURN, Mass. & TOKYO--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo, Co. Ltd. (TSE 4568) announced today the execution of a license agreement for the development of a new AKT ...
Business Wire

ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), ...
Business Wire

Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology ...

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University ...
FierceBiotech

ArQule Regains Worldwide Rights to AKT Program

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR WOBURN, Mass.--(4/1/2103)--ArQule, Inc. (NASDAQ: ARQL) today announced it has regained ...